Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Measuring Sleep Disturbance Among Cancer Patients
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, October 2008
Sponsored by: M.D. Anderson Cancer Center
Information provided by: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00505544
  Purpose

Primary Objectives:

  • To establish concurrent criterion-related validity of the Brief Sleep Disturbance Scale (BSDS) by correlating the scale with the Pittsburgh Sleep Quality Index.
  • To evaluate the construct validity of the BSDS through exploratory factor analysis.
  • To examine possible predictors of sleep disturbance.
  • To evaluate the reliability of the BSDS using Cronbach's coefficient alpha and test-retest reliability.
  • To evaluate the sensitivity of the BSDS by administering it to the same group of patients (n = 60) prior to treatment with a regimen associated with sleep disturbance, during 4 weeks of treatment, and upon completion of treatment.
  • To evaluate the psychometric properties of the BSDS in a sample of community dwelling adults.

Secondary Objective:

  • To obtain pilot data from a small sample of patients who will wear an actigraph for one week.

Condition Intervention
Advanced Cancer
Behavioral: Questionnaire
Device: Actigraph

MedlinePlus related topics: Cancer Sleep Disorders
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: The Brief Sleep Disturbance Scale: Measuring Sleep Disturbance Among Cancer Patients

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • To learn about the sleep disturbance that many people with cancer experience during and after their cancer treatments. [ Time Frame: 4 Years ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 570
Study Start Date: August 2005
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Questionnaire
Behavioral: Questionnaire
Questionnaires that ask about your sleep, symptoms, and mood.
2
Questionnaire + Actigraphs
Behavioral: Questionnaire
Questionnaires that ask about your sleep, symptoms, and mood.
Device: Actigraph
Wear actigraph to collect information on activity levels and sleep patterns for one week.

Detailed Description:

Patients Who Complete the Surveys on Multiple Time Points:

This study will teach researchers about changes in your sleep patterns that may happen during your cancer treatment. The participants will be recruited from the Melanoma Clinic.

If you agree to take part in this study, during your cancer treatment, you will be asked to complete three written questionnaires that ask about your sleep, symptoms, and mood. These questionnaires will take about 20 minutes to complete. You will be asked to complete the questionnaires before, during and after your cancer treatment during 11 of your clinic visits.

You will also be asked to fill out a sleep diary at home, in which you will be asked to record what time you go to bed, whether you get up during the night, and what time you wake up. You will be asked to fill out the diary every day, for one week. You will be asked to return it during a clinic visit or by mail, with a stamped envelope that will be provided.

During the study, the research staff will collect information from your medical chart about your cancer, cancer treatment, and laboratory tests.

This is an investigational study. Up to 570 participants will take part in this multicenter study. Up to 380 will be enrolled at M. D. Anderson.

Patients Who Wear Actigraphs:

This study will help researchers to understand how cancer and cancer treatments affect sleep patterns. The participants will be recruited from the M. D. Anderson outpatient clinics, including Breast, Neuro-oncology, Blood and Marrow Transplantation, Genitourinary Oncology, Gastrointestinal Oncology Gynecologic Oncology, Head and Heck, Thoracic Oncology, Leukemia, Lymphoma, Melanoma, Sarcoma, Internal Medicine, and the Ambulatory Treatment Center.

If you agree to take part in this study, you will be asked to complete eight written questionnaires that have questions about your sleep, symptoms, and mood. These questionnaires will take about 20 minutes to complete. You will be asked to fill out the questionnaires before wearing the actigraph and after one week of wearing the actigraph.

During the study, the research staff will collect information from your medical chart about the cancer, cancer treatment, and laboratory tests.

You will be asked to wear an actigraph on your wrist for one week. An actigraph is a small motion detector that is about the size and shape of a wristwatch. The actigraph will collect and store information on your activity levels and your sleep patterns. You will be asked to return the actigraph at the end of the week.

You will be asked to fill out a sleep diary at home, in which you will be asked to record what time you go to bed, whether you get up during the night, and what time you wake up. You will only be asked to do this during the week you wear the actigraph.

At the end of the "actigraph" week, you will be asked to complete a brief sleep questionnaire, which will take about 5 minutes to complete.

This is an investigational study. About 20 patients will take part in this study. All will be enrolled at M. D. Anderson.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Study participants with a pathological diagnosis of cancer and community dwelling adults who attend a meeting of a designated service organization.

Criteria

Inclusion Criteria:

  1. Outpatient or inpatient receiving evaluation, treatment, or follow-up care at MDACC or a collaborating site.
  2. Has a pathological diagnosis of cancer.
  3. 18 years of age or older.
  4. Able to understand English.
  5. Gives informed consent to participate.
  6. Community sample eligibility: Community dwelling adult who attends a meeting of a designated service organization.
  7. Community sample eligibility: 18 years of age or older
  8. Community sample eligibility: Gives Informed Consent to participate.
  9. Community sample eligibility: Able to understand English.

Exclusion Criteria:

  1. Cannot understand the intent of the study.
  2. Patient feels too ill to complete the surveys.
  3. Refuses to participate.
  4. Community sample exclusion criterion: Unable to complete the surveys.
  5. Community sample exclusion criterion: Refuses to participate.
  6. Community sample exclusion criterion: Cancer diagnosis (past or present).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00505544

Contacts
Contact: Karen O. Anderson, PhD 713-745-3470

Locations
United States, Texas
U.T. M.D. Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Karen O. Anderson, PhD            
Lyndon Baines Johnson General Hospital Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Karen O. Anderson, PhD M.D. Anderson Cancer Center
  More Information

UT MD Anderson Cancer Center website  This link exits the ClinicalTrials.gov site

Responsible Party: U.T.M.D. Anderson Cancer Center ( Karen O. Anderson, PhD/Associate Professor )
Study ID Numbers: 2004-0598
Study First Received: July 19, 2007
Last Updated: November 20, 2008
ClinicalTrials.gov Identifier: NCT00505544  
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Advanced Cancer
Questionnaire
Survey
Sleep Disturbance
Sleep Quality

Study placed in the following topic categories:
Signs and Symptoms
Mental Disorders
Neurologic Manifestations
Dyssomnias
Sleep Disorders

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009